

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-10 (canceled)

11. (Previously Presented) A method for preventing or treating:
neointimal proliferation and thickening and/or restenosis and/or vascular occlusion following
vascular injury, or
manifestations of chronic rejection in a recipient of organ or tissue transplant, or
acute or chronic rejection in a recipient of organ or tissue xenograft transplant,
comprising administering to the patient an effective amount of 40-O-(2-hydroxy)ethyl-
rapamycin with an effective amount of a second agent selected from the group consisting of a
cyclosporin or an immunosuppressive analog thereof, an ascomycin or immunosuppressive analog
thereof, a corticosteroid, cyclophosphamide, azathioprene, methotrexate, brequinar, leflunomide,
mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxysperguatine, immunosuppressive
monoclonal antibodies, and CTLA4-Ig.
12. (Previously Presented) The method of Claim 11 wherein the second agent is cyclosporin A,
cyclosporin G, FK-506 or monoclonal antibodies to leukocyte receptors or to their ligands.
13. (Previously Presented) The method of Claim 11 wherein the second agent is monoclonal
antibodies to MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45, CD58, or to ligands thereof.
14. (Previously Presented) The method of Claim 13 wherein the second agent is monoclonal
antibodies to CD3.
15. (Previously Prevented) The method of Claim 11 wherein the second agent is cyclosporin A.
16. Previously Presented) The method of Claim 11 wherein the second agent is cyclosporin G.

17. (Previously Presented) The method of Claim 11 wherein the second agent is mycophenolic acid.
18. (Previously Presented) The method of Claim 11 wherein the second agent is CTLA4lg.
19. (Previously Presented) The method of Claim 11 wherein the second agent is mycophenolate mofetil.
20. (Previously Presented) A method for preventing or treating:
neointimal proliferation and thickening and/or restenosis and/or vascular occlusion following vascular injury,
comprising administering to the patient an effective amount of 40-O-(2-hydroxy)ethyl-rapamycin with an effective amount of a second agent selected from the group consisting of a cyclosporin or an immunosuppressive analog thereof, an ascomycin or immunosuppressive analog thereof, a corticosteroid, cyclophosphamide, azathioprene, methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxysperguatine, immunosuppressive monoclonal antibodies, and CTLA4-Ig.
21. (Previously Presented) The method of Claim 20 wherein the second agent is cyclosporin A, cyclosporin G, FK-506 or monoclonal antibodies to leukocyte receptors or to their ligands.
22. (Previously Presented) The method of Claim 20 wherein the second agent is monoclonal antibodies to MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45, CD58, or to ligands thereof.
23. (Previously Presented) The method of Claim 22 wherein the second agent is monoclonal antibodies to CD3.

24. (Previously Presented) The method of Claim 20 wherein the second agent is cyclosporin A.
25. (Previously Presented) The method of Claim 20 wherein the second agent is cyclosporin G.
26. (Previously Presented) The method of Claim 20 wherein the second agent is mycophenolic acid.
27. (Previously Presented) The method of Claim 20 wherein the second agent is CTLA4Ig.
28. (Previously Presented) The method of Claim 20 wherein the second agent is mycophenolate mofetil.